Literature DB >> 7882301

Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma.

N Ito1, S Kawata, S Tamura, Y Shirai, S Kiso, H Tsushima, Y Matsuzawa.   

Abstract

Transforming growth factor-beta 1 (TGF-beta 1) has been implicated in tumor progression by promoting angiogenesis or suppressing immune system. We reported previously that transforming growth factor-beta 1 (TGF-beta 1) is overproduced by human hepatocellular carcinoma (HCC) tissues and that plasma TGF-beta 1 levels are elevated in patients with HCC. In the present study, we investigated the relationship between plasma TGF-beta 1 levels and tumor vascularity as assessed by conventional celiac angiography in 17 patients with HCC. The plasma TGF-beta 1 level did not correlate with tumor size or underlying liver disease. However, we found that plasma TGF-beta 1 levels correlated positively with the tumor vascularity. These results suggest that excessive TGF-beta 1 production may contribute to tumor angiogenesis in HCC.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7882301     DOI： 10.1016/0304-3835(95)90156-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  21 in total

1.  Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro.

Authors:  Feray Kockar; Hatice Yildrim; Rahsan Ilikci Sagkan; Carsten Hagemann; Yasemin Soysal; Jelena Anacker; Ahmed Ayad Hamza; Dirk Vordermark; Michael Flentje; Harun M Said
Journal:  World J Clin Oncol       Date:  2012-06-10

Review 2.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

Review 3.  TGF-β Family Signaling in Tumor Suppression and Cancer Progression.

Authors:  Joan Seoane; Roger R Gomis
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

4.  Preoperative administration of polysaccharide Kureha and reduced plasma transforming growth factor-β in patients with advanced gastric cancer: A randomized clinical trial.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Hiroaki Mieno; Masayuki Nemoto; Tomotaka Shibata; Natsuya Katada; Shigeaki Ohtsuki; Yasutoshi Sakamoto; Keika Hoshi; Guoqin Wang; Osamu Hemmi; Toshihiko Satoh; Shiro Kikuchi; Masahiko Watanabe
Journal:  Mol Clin Oncol       Date:  2015-01-19

Review 5.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

Review 6.  Transforming growth factor-β: A therapeutic target for cancer.

Authors:  Sulsal Haque; John C Morris
Journal:  Hum Vaccin Immunother       Date:  2017-06-02       Impact factor: 3.452

7.  Restoring TGFbeta function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation.

Authors:  Janindra Warusavitarne; Fiona McDougall; Keshani de Silva; Rebecca Barnetson; Marinella Messina; Bruce G Robinson; Margaret Schnitzler
Journal:  Int J Colorectal Dis       Date:  2008-11-05       Impact factor: 2.571

Review 8.  Inflammation and liver tumorigenesis.

Authors:  Beicheng Sun; Michael Karin
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

9.  Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.

Authors:  Chia-Lin Chen; Hidekazu Tsukamoto; Jian-Chang Liu; Claudine Kashiwabara; Douglas Feldman; Linda Sher; Steven Dooley; Samuel W French; Lopa Mishra; Lydia Petrovic; Joseph H Jeong; Keigo Machida
Journal:  J Clin Invest       Date:  2013-06-10       Impact factor: 14.808

10.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Authors:  Swati Biswas; Marta Guix; Cammie Rinehart; Teresa C Dugger; Anna Chytil; Harold L Moses; Michael L Freeman; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2007-04-05       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.